Skip to content

Cytokinetics CYTK Reimbursements — Revenue

Discontinued — last reported Q4 '20

Similar metrics at other companies

Exelixis logo
EXELCollaboration Research And Development Service — Revenue
$12.49M+26.5%
Summit Therapeutics logo
SMMTResearch collaboration agreement — Revenue
$0
Exelixis logo
EXELResearchand Development — Revenue
$12.99M+23.0%
Ionis Pharmaceuticals logo
IONSCollaborative Agreement Revenue — Revenue
$120.66M+168%
Ionis Pharmaceuticals logo
IONSResearch And Development Revenue Under Collaborative Agreements — Revenue
$352.74M+81.2%
Incyte logo
INCYMilestone And Contract Revenue — Revenue
$18M+260%

Other financials

Income statement

See full
Revenue$19.4M+1,126%
Operating income-$183.6M-18.0%
Net income-$206.0M-27.7%
EPS (diluted)-$1.67-22.8%

Balance sheet

See full
Cash & equivalents$129.8M+76.2%
Total debt$418.2M+75.8%
Total equity-$826.6M-210%
Total assets$1.3B+0.7%

Cash flow

See full
Operating cash flow-$145.5M-10.5%
CapEx$5.9M+4.7%
Free cash flow-$151.4M-10.3%

Valuation

See full
Market cap$10.7B+70.6%
Enterprise value$10.98B+70.7%
P/S101.1×-225×

Profitability

See full
Operating margin-605.1%-268pp
Net margin-784%-337pp
FCF margin-518.8%-223pp

Returns & leverage

See full
Return on equity-337.6%
Debt / equity2.2×
Current ratio4.2×-1.8×

Where this comes from

Reported directly by Cytokinetics in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Cytokinetics’s 10-K, filed February 26, 2021, on SEC EDGAR. View the filing →

Questions, answered.

What does reimbursements — revenue mean?
Revenue earned by performing specific research or development services for a partner under a contractual agreement.
How do you interpret reimbursements — revenue?
An increase suggests successful execution of collaborative research programs or expanded partnership activity, while a decrease may indicate the completion of specific milestones or a shift in partnership strategy.
How does reimbursements — revenue compare across companies?
Comparable to 'Collaboration Revenue' or 'Contract Research Revenue' reported by other clinical-stage biopharmaceutical companies engaged in co-development or licensing agreements.